Observational studyFrontiers in endocrinology2024
Quantitative and qualitative assessment of a pituitary neuroendocrine tumor's T2-signal intensity in acromegaly - a call for unification.
Observational study in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.The Journal of clinical endocrinology and metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The T2-signal intensity (SI) of somatotroph pituitary neuroendocrine tumors (sPitNET) is associated with treatment response and granulation pattern. Our aim was to evaluate SI assessment methods and their clinical implications, including responsiveness to preoperative first-generation somatostatin analogs (SSA). Methods: This single-center, observational study included unselected, consecutive patients with newly diagnosed acromegaly. Out of 109 treatment-naïve patients, 69 were eligible. The qualitative Visual Method involved a visual comparison of the sPitNET with the temporal gray matter. The Three Tissue Method compared the quantified SI of the sPitNET, temporal white matter, and gray matter. The signal intensity ratio of the sPitNET vs. gray matter (GM-SIR) was calculated. Tumors were divided into three groups: hyperintense (HYPER), isointense (ISO), and hypointense (HYPO) according to the Visual Method, Three Tissue Method, and GM-SIR. These groups were compared in terms of demographic, radiological, and biochemical features. The SI assessment methods were investigated for their ability to predict preoperative SSA responsiveness. Results: SI assessment methods classified SI type correspondingly in 58-75.4% of cases. ISO constituted 39-49% of the analyzed sPitNETs. All methods identified significant differences in tumor volume between the SI groups, with HYPO being more biochemically active per tumor volume unit. According to the Three Tissue Method, patients with ISO had the youngest age at diagnosis and onset. According to the Visual Method, ISO had a lower chance of achieving insulin-like growth factor 1 (IGF1) normalization compared to HYPO (odds ratio (OR) 0.089, confidence interval (CI) 0.015-0.538, p= 0.008)), with no differences between HYPER and HYPO. Only the Visual Method predicted the IGF1 normalization after SSA. HYPER and ISO sPitNETs were classified in electron microscopy as both densely and sparsely granulated. Bihormonal tumors presented only as HYPO and ISO. According to the Three Tissue Method, no HYPO was diagnosed with sparse granulation. Discussion: We demonstrated discrepancies between the SI assessment methods. The Visual Method predicted the outcome of preoperative treatment with SSA. Clinically, ISO behaved similarly to HYPER. Further studies are needed to unify SI assessment and improve its clinical applicability in acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.